Ocular Therapeutix (OCUL) Updates AXPAXLI NDA Progress for Macular Degeneration

Ocular Therapeutix (OCUL) provided an update on its New Drug Application (NDA) for AXPAXLI, an investigational treatment for wet age-related macular degeneration (wet AMD), during its Investor Day event on June 22, 2026. This regulatory development is a key focus for the company as it progresses its ophthalmic pipeline. AXPAXLI, formerly known as OTX-TAD, is an intravitreal implant designed for sustained delivery of axitinib. The NDA submission represents a critical milestone towards potential market approval, addressing a significant unmet medical need within the wet AMD patient population. The company's continued advancement of AXPAXLI through the regulatory process is central to its strategic growth, aiming to strengthen its position in the ophthalmic therapeutics market.